'Supplementary figure 1' presentation slideshows

Supplementary Figure 1

Supplementary Figure 1. Kantidakis and White. 400ng. 200ng. 100ng. RNA:. Dr1 mRNA. 5S rRNA. pre-tRNA LEU. pre-tRNA TYR. tRNA Met. Alu RNA. 7SL RNA. U6 snRNA. ARPP P0 mRNA. Repression of tRNA genes by Dr1. Supplementary Figure 2. Kantidakis and White. A. Dr1 RNAi. control.

181 views • 9 slides

Supplementary Figures 1-3

Supplementary Figures 1-3 The protein tyrosine-phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis Kathleen Spring 1# , Patrick Fournier 1# , Line Lapointe 1 , Catherine Chabot 1 , Jacinthe Roussy 1 , Sandra Pommey 1 , John Stagg 1, 2 , and Isabelle Royal 1, 3

337 views • 5 slides

Supplementary Figure 1

Supplementary Figure 1. HUVEC. A549. ACHN. DU145. kDa. - 150. NRP1. - 102. - 150. NRP2. - 102. - 225. VEGFR-1. - 150. - 225. VEGFR-2. - 150. - 38. GAPDH. - 31. NRP1. GAPDH. Supplementary Figure 2. C. siRNA. C. #4914. #4820. kDa. - 150. - 102. - 38. - 31.

107 views • 3 slides

Supplementary Figure 1

Supplementary Figure 1. A. B. C. D. E. A: 0. B: 1+. C: 2+. D: 3+. E: Normal bronchial epithelium. Supplementary Table 1. Summary of Tumors with Intrinsic Resistance.

183 views • 3 slides

Control (MAAII) Sialidase (MAAII) Buffer (MAAII)

Supplementary Figure 1. ATI-like. ATII. AMs. PBDMs. A. b. a. c. d. Control (MAAII) Sialidase (MAAII) Buffer (MAAII). e. f. g. h. i. j. k. l. Supplementary Figure 1. ATI-like. ATII. AMs. PBDMs. B. b. a. c. d. Control (SNA) Sialidase (SNA) Buffer (SNA). e. f.

97 views • 3 slides

Supplementary Figure 1. Heat map using Ingenuity Analysis

112 views • 2 slides

Supplementary Figure 1.

Supplementary Figure 1. .

104 views • 1 slides

Supplementary figure 1

Dorsal administration of 1% DNCB. Oral / Dorsal administration of C6. 8. 3. 7. Week s 0. 1. 5. 6. 2. 4. Dorsal administration of 0.3% DNCB. Supplementary figure 1.

62 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1.

63 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. A. rate of PDPN expression. CAF4: PDPN. 13.48%. 14.38%. CAF1. Time of trypsin/EDTA treatment (min). B. Cultured CAFs. CTRL. 2min. 13.87%. CAF2. CAF3. CAF4. CAF1. CAF3. CAF4. CAF2. Harvested CAFs. 5min. 10min. CAF1. CAF3. CAF4. CAF2. C.

113 views • 1 slides

Supplementary Figure 1

i. ii. iii. iv. Supplementary Figure 1.

65 views • 1 slides

GSTPi

clones. mass cultures. BMhTERT-1. BMhTERT-2. BM2A2. BM2B8. BM2A7. BM2A11. BM2B2. BM2A6. BM2A10. BM10A3. BM2A9. BM10B1. BM2B12. BMEC. p16 INK4a + + + + - + + + + + + + - - - -. kDa. 23. GSTPi. 42. Actin.

131 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. a. d. BMDM. BMDM. b. BMDM. e. BMDM. c. BMDM.

78 views • 1 slides

polyI:C

polyI:C. CpG. LPS. 0.32. 2.35. 0.92. 3.04. 0.83. 2.09. SSC. 95. 2.36. 92.8. 3.22. 95.2. 1.89. untreated. 0.65. 2.69. PI. 95.1. 1.56. A. polyI:C. CpG. LPS. untreated. 72.7. 66.1. 65.8. 69.6. FSC. B. Annexin V. Supplementary Figure 1

167 views • 1 slides

Trapped allele

Supplementary Figure 1. frt. F3. frt. F3. lx5171. lxP. lxP. lx5171. E1. OPE. OPE. OPE. OPE. OPE. OPE. E2. pA. SA. b geo. pA. inversion at F3 sites. inversion at frt sites. E1. E2. pA. OPE. OPE. OPE. OPE. OPE. OPE. SA. b geo. pA. Inversion by FLP. E1. OPE. OPE.

113 views • 1 slides

Supplementary figure 1

Supplementary figure 1. Viable. Viable. Apoptotic. Apoptotic. Necrotic. Necrotic. 120. SKOV-3. 100. 80. 60. % total number of cells. 40. 20. 0. 0 hr. 24 hr. 48 hr. 72 hr. 96 hr. - 22 kDa. WB:. - 15 kDa. ? Bid ? G3PDH. - 37 kDa. Caov-4. SKOV-3. A. 120. Caov-4. 100.

85 views • 1 slides

Supplementary Figure 1

Nephrin. Nephrin. Nephrin. Nephrin. Nephrin. Synaptopodin. Synaptopodin. Synaptopodin. Synaptopodin. Synaptopodin. A. Merge. Merge. Merge. Merge. Merge. B. Podocin. Podocin. Podocin. Podocin. Podocin. Day 28. Control. Day 3. Day 15. Day 7. ADRN 11 mg/kg. Cont. Day3.

65 views • 1 slides

CD3

Supplementary Figure 1. C5aR-/- to C5aR-/-. WT to WT. CD3. Gr-1.

143 views • 1 slides

7AAD

Overlay. 7AAD. Myosin heavy chain. S3RNAi treated. Controls. Supplementary figure 1. myosin heavy chain protein levels ( reen ) in S3RNAi treated C2C12 cells is decreased in comparison to controls after 72 h in DM. Nuclei were counter-stained with 7-AAD (red).

170 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. A. MIG (pMSCV-ires-GFP). I. GFP. LTR. LTR. MIG-PL2 (pMSCV-PLAGL2-ires-GFP). PL2. GFP. LTR. LTR. I. B. CBFb-MYH11 + HPs. GFP sort. Gene expression profile. Genes commonly deregulated in PL2+ cells. MIG-PL2 transduction. MIG transduction. GFP sort.

121 views • 1 slides